Previous studies have shown that SFRP1 can be used as a prognostic marker in breast cancer [36–38] and SFRP1 might be used as a marker for chemotherapy and neoadjuvant chemotherapy response in triple-negative breast cancer [39, 40]. The gene discussed is SFRP1; the disease is triple-negative breast carcinoma.